Curis Inc (CRIS) 3.23 $CRIS
Strength Seen in Curis (CRIS): Stock Moves 9.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:25AM CST
Curis (CRIS) was a big mover last session, with shares rising over 9% on the day.
CRIS: 3.23 (+0.25), AFFX: 11.45 (+0.02)
Curis Up 5.1%, Shares Break Through Resistance (CRIS)
Comtex SmarTrend(R) - Thu Feb 12, 10:42AM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 5.1% to $2.87 on 1.3x average daily volume. Thus far today, Curis has traded 1.2 million shares, vs. average volume of 867,000 shares per day. The stock has outperformed the Dow (5.1% to the Dow's 0.2%) and outperformed the S&P 500 (5.1% to the S&P's 0.5%) during today's trading.
CRIS: 3.23 (+0.25)
Strong On High Relative Volume: Curis (CRIS)
at The Street - Tue Feb 10, 9:03AM CST
Trade-Ideas LLC identified Curis (CRIS) as a strong on high relative volume candidate
CRIS: 3.23 (+0.25)
Curis to Present at the 2015 Bio CEO and Investor Conference
GlobeNewswire - Tue Feb 03, 6:13AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that the Company will present at the 2015 Bio CEO and Investor Conference at 2:30 p.m. ET on Tuesday, February 10, 2015, in New York City.
CRIS: 3.23 (+0.25)
Dr. Reddy's (RDY) Q3 Earnings Down 7% Y/Y, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 9:50AM CST
Dr. Reddy's Laboratories (RDY) reported third-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 53 cents, down 7% from the year-ago quarter.
MNK: 115.01 (+2.51), CRIS: 3.23 (+0.25), RDY: 54.15 (-0.01), NVS: 102.20 (-0.17)
Seeking Alpha's Biotech Weekly: Salix Sale Murmurs, A Very Active CHMP, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jan 23, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CRIS: 3.23 (+0.25), NAVB: 1.60 (unch), TROV: 4.99 (-0.17), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), ABBV: 58.05 (+1.00), ARIA: 7.35 (+0.45), ARNA: 4.55 (+0.02), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
3 Attractive Biotech Picks For 2015
Bret Jensen - at Seeking Alpha - Fri Jan 23, 8:44AM CST
CRIS: 3.23 (+0.25), GILD: 101.90 (+1.10), EGRX: 20.98 (+1.45)
Curis (CRIS) in Focus: Stock Adds 17.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 7:51AM CST
Curis, Inc. (CRIS) was a big mover last session, as its shares rose almost 18% on the day.
CRIS: 3.23 (+0.25), RDY: 54.15 (-0.01)
Curis Up on Immuno-Oncology Agreement with Aurigene - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 5:35PM CST
Curis (CRIS) inked an exclusive collaboration agreement with Aurigene Discovery Technologies Limited, an independent, wholly owned subsidiary of Dr. Reddy's Laboratories Ltd. with a focus on immuno-oncology and selected precision oncology targets.
CRIS: 3.23 (+0.25), AMGN: 153.48 (+0.30), RDY: 54.15 (-0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:45AM CST
HSGX: 8.61 (-0.07), CRIS: 3.23 (+0.25), NES: 3.52 (+0.13), TZOO: 9.88 (+0.49), WLT: 1.09 (+0.05), FXCM: 2.21 (-0.01), NNVC: 2.97 (-0.05), VLTC: 0.77 (-0.04), CYN: 90.32 (+0.49), ANR: 1.27 (+0.03), OTIC: 31.14 (+0.13), MHR: 2.62 (+0.11), EGLT: 10.60 (+0.58), NERV: 4.68 (+0.09), FFIV: 116.64 (+1.37), KEG: 2.14 (+0.08), CTP: 6.53 (+0.13), ENRJ: 2.81 (+0.06), LE: 35.84 (+0.19)
Traders Get Bullish on Shares of Curis, Shares Up 7.7% (CRIS)
Comtex SmarTrend(R) - Thu Jan 22, 10:06AM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 7.7% to $1.54 on 1.0x average daily volume. Curis has traded 556,000 shares thus far today, vs. average volume of 544,000 shares per day. The stock has outperformed the Dow (7.7% to the Dow's 0.9%) and outperformed the S&P 500 (7.7% to the S&P's 0.9%) during today's trading.
CRIS: 3.23 (+0.25)
Curis teams up with Aurigene in cancer
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 6:50AM CST
CRIS: 3.23 (+0.25)
Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets
GlobeNewswire - Wed Jan 21, 5:05AM CST
-- Agreement Provides Curis with Option to Exclusively License Aurigene's Antagonists for Immuno-Oncology, Including an Antagonist of PD-L1 and Selected Precision Oncology Targets, Including an IRAK4 Kinase Inhibitor --
CRIS: 3.23 (+0.25), RDY: 54.15 (-0.01)
LeeAnn Ali Joins BioBridges as Executive Director, Clinical Operations
Marketwired - Tue Jan 13, 7:03AM CST
BioBridges, a leading contract consulting company servicing the pharma, biotech, and medical device industries, proudly announces the addition of LeeAnn Ali to the BioBridges family. Ali brings over 20 years of industry experience to her new role as Executive Director, Clinical Operations.
JNJ: 99.62 (+1.18), CRIS: 3.23 (+0.25), DYAX: 15.00 (-0.16)
Curis (CRIS) Surges: Stock Moves 11.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 8:11AM CST
Curis, Inc. (CRIS) was a big mover last session, as the company saw its shares rise nearly 12% on the day.
CRIS: 3.23 (+0.25), ACOR: 36.14 (-0.51)
Hot Stock: Curis, Shares Gain 5.6% (CRIS)
Comtex SmarTrend(R) - Tue Dec 30, 11:34AM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 5.6% to $1.33 on 1.2x average daily volume. Thus far today, Curis has traded 607,000 shares, vs. average volume of 488,000 shares per day. The stock has outperformed the Dow (5.6% to the Dow's -0.3%) and outperformed the S&P 500 (5.6% to the S&P's -0.3%) during today's trading.
CRIS: 3.23 (+0.25)
Curis Announces Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients With Advanced/ Relapsed Solid Tumors
GlobeNewswire - Thu Dec 18, 6:06AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that the first patient has initiated treatment with CUDC-907 in a Phase 1 clinical trial in patients with advanced or relapsed solid tumors, including hormone receptor positive (HR+)/ HER2-negative breast cancer or midline carcinoma with certain NUT gene rearrangements. CUDC-907 is an oral, dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes that is currently under investigation in the first-in-human Phase 1 clinical study in patients with relapsed or refractory lymphomas and multiple myeloma.
CRIS: 3.23 (+0.25)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Strength Seen in Curis (CRIS): Stock Moves 9.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:25AM CST
Curis (CRIS) was a big mover last session, with shares rising over 9% on the day.
CRIS: 3.23 (+0.25), AFFX: 11.45 (+0.02)
Curis Up 5.1%, Shares Break Through Resistance (CRIS)
Comtex SmarTrend(R) - Thu Feb 12, 10:42AM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 5.1% to $2.87 on 1.3x average daily volume. Thus far today, Curis has traded 1.2 million shares, vs. average volume of 867,000 shares per day. The stock has outperformed the Dow (5.1% to the Dow's 0.2%) and outperformed the S&P 500 (5.1% to the S&P's 0.5%) during today's trading.
CRIS: 3.23 (+0.25)
Strong On High Relative Volume: Curis (CRIS)
at The Street - Tue Feb 10, 9:03AM CST
Trade-Ideas LLC identified Curis (CRIS) as a strong on high relative volume candidate
CRIS: 3.23 (+0.25)
Curis to Present at the 2015 Bio CEO and Investor Conference
GlobeNewswire - Tue Feb 03, 6:13AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that the Company will present at the 2015 Bio CEO and Investor Conference at 2:30 p.m. ET on Tuesday, February 10, 2015, in New York City.
CRIS: 3.23 (+0.25)
Dr. Reddy's (RDY) Q3 Earnings Down 7% Y/Y, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 9:50AM CST
Dr. Reddy's Laboratories (RDY) reported third-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 53 cents, down 7% from the year-ago quarter.
MNK: 115.01 (+2.51), CRIS: 3.23 (+0.25), RDY: 54.15 (-0.01), NVS: 102.20 (-0.17)
Seeking Alpha's Biotech Weekly: Salix Sale Murmurs, A Very Active CHMP, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jan 23, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CRIS: 3.23 (+0.25), NAVB: 1.60 (unch), TROV: 4.99 (-0.17), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), ABBV: 58.05 (+1.00), ARIA: 7.35 (+0.45), ARNA: 4.55 (+0.02), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
3 Attractive Biotech Picks For 2015
Bret Jensen - at Seeking Alpha - Fri Jan 23, 8:44AM CST
CRIS: 3.23 (+0.25), GILD: 101.90 (+1.10), EGRX: 20.98 (+1.45)
Curis (CRIS) in Focus: Stock Adds 17.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 7:51AM CST
Curis, Inc. (CRIS) was a big mover last session, as its shares rose almost 18% on the day.
CRIS: 3.23 (+0.25), RDY: 54.15 (-0.01)
Curis Up on Immuno-Oncology Agreement with Aurigene - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 5:35PM CST
Curis (CRIS) inked an exclusive collaboration agreement with Aurigene Discovery Technologies Limited, an independent, wholly owned subsidiary of Dr. Reddy's Laboratories Ltd. with a focus on immuno-oncology and selected precision oncology targets.
CRIS: 3.23 (+0.25), AMGN: 153.48 (+0.30), RDY: 54.15 (-0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:45AM CST
HSGX: 8.61 (-0.07), CRIS: 3.23 (+0.25), NES: 3.52 (+0.13), TZOO: 9.88 (+0.49), WLT: 1.09 (+0.05), FXCM: 2.21 (-0.01), NNVC: 2.97 (-0.05), VLTC: 0.77 (-0.04), CYN: 90.32 (+0.49), ANR: 1.27 (+0.03), OTIC: 31.14 (+0.13), MHR: 2.62 (+0.11), EGLT: 10.60 (+0.58), NERV: 4.68 (+0.09), FFIV: 116.64 (+1.37), KEG: 2.14 (+0.08), CTP: 6.53 (+0.13), ENRJ: 2.81 (+0.06), LE: 35.84 (+0.19)
Traders Get Bullish on Shares of Curis, Shares Up 7.7% (CRIS)
Comtex SmarTrend(R) - Thu Jan 22, 10:06AM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 7.7% to $1.54 on 1.0x average daily volume. Curis has traded 556,000 shares thus far today, vs. average volume of 544,000 shares per day. The stock has outperformed the Dow (7.7% to the Dow's 0.9%) and outperformed the S&P 500 (7.7% to the S&P's 0.9%) during today's trading.
CRIS: 3.23 (+0.25)
Curis teams up with Aurigene in cancer
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 6:50AM CST
CRIS: 3.23 (+0.25)
Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets
GlobeNewswire - Wed Jan 21, 5:05AM CST
-- Agreement Provides Curis with Option to Exclusively License Aurigene's Antagonists for Immuno-Oncology, Including an Antagonist of PD-L1 and Selected Precision Oncology Targets, Including an IRAK4 Kinase Inhibitor --
CRIS: 3.23 (+0.25), RDY: 54.15 (-0.01)
LeeAnn Ali Joins BioBridges as Executive Director, Clinical Operations
Marketwired - Tue Jan 13, 7:03AM CST
BioBridges, a leading contract consulting company servicing the pharma, biotech, and medical device industries, proudly announces the addition of LeeAnn Ali to the BioBridges family. Ali brings over 20 years of industry experience to her new role as Executive Director, Clinical Operations.
JNJ: 99.62 (+1.18), CRIS: 3.23 (+0.25), DYAX: 15.00 (-0.16)
Curis (CRIS) Surges: Stock Moves 11.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 8:11AM CST
Curis, Inc. (CRIS) was a big mover last session, as the company saw its shares rise nearly 12% on the day.
CRIS: 3.23 (+0.25), ACOR: 36.14 (-0.51)
Hot Stock: Curis, Shares Gain 5.6% (CRIS)
Comtex SmarTrend(R) - Tue Dec 30, 11:34AM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 5.6% to $1.33 on 1.2x average daily volume. Thus far today, Curis has traded 607,000 shares, vs. average volume of 488,000 shares per day. The stock has outperformed the Dow (5.6% to the Dow's -0.3%) and outperformed the S&P 500 (5.6% to the S&P's -0.3%) during today's trading.
CRIS: 3.23 (+0.25)
Curis Announces Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients With Advanced/ Relapsed Solid Tumors
GlobeNewswire - Thu Dec 18, 6:06AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that the first patient has initiated treatment with CUDC-907 in a Phase 1 clinical trial in patients with advanced or relapsed solid tumors, including hormone receptor positive (HR+)/ HER2-negative breast cancer or midline carcinoma with certain NUT gene rearrangements. CUDC-907 is an oral, dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes that is currently under investigation in the first-in-human Phase 1 clinical study in patients with relapsed or refractory lymphomas and multiple myeloma.
CRIS: 3.23 (+0.25)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
